Latest news

• Roche faces biosimilar blitz in 2018

  Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

• Biogen cuts $217m deal for Karyopharm neurology drug

  Biogen reported 2017 revenues of $12.3bn, up 15% on the prior year, thanks to gains for its multiple sclerosis drugs, particularly Tecfidera (dimethyl fumarate) and rising royalties from Ocrevus (ocrelizumab) -

• Roche’s Ocrevus is first primary progressive MS drug in EU

  Roche’s CD20-targeting antibody Ocrevus has become the first and only drug to be approved in the EU for the primary progressive for of multiple sclerosis (PPMS). ... In the ORATORIO study, Ocrevus was able to slow disability progression by around 24%

• Smartphone monitoring shows its worth in Roche MS trial

  The latest results from the FLOODLIGHT clinical trial programme show that additional, real-world data using smartphone or smartwatch technology given to patients treated with Roche’s MS therapy Ocrevus (ocrelizumab),

• Ocrevus off to a flying start as Roche raises 2017 forecasts

  new multiple sclerosis drug Ocrevus, which brought in 192m Swiss francs ($200m) in its first quarter on the market. ... Ocrevus (ocrelizumab) only reached the market at the end of March, and Roche's decision to set a competitively low price for the drug